News

Based on the average brokerage recommendation (ABR), Veeva (VEEV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Brown Advisory, an investment management company, released its “Brown Large-Cap Growth Strategy” for the first-quarter 2026 investor letter. A copy of the letter is available to download here. The Brown Advisory Large-Cap Growth Strategy experienced a decline in the first quarter of 2026, modestly trailing the Russell 1000 Growth Index. Despite negative absolute returns amidst volatility, […]

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Veeva Systems Inc. (NYSE:VEEV) is one of the 10 Best SaaS Stocks to Buy According to Reddit. According to a June 29 report by Investing.com, Stifel reiterated its $230 price target and maintained a Buy rating on the stock following the company’s acquisition of Copli. Earlier on June 23, Veeva announced the acquisition of the […]

A number of stocks jumped in the afternoon session after Guggenheim's John DiFucci upgraded both Salesforce and ServiceNow to Buy, arguing the AI-disruption fear that gutted the sector during the year had pushed valuations too low. This was a valuation call from a skeptic, not an AI endorsement.

Veeva Systems Inc. (NYSE:VEEV) was added to the S&P 500 in early May and thus appears on our list of the 10 stocks that were added to the S&P 500 index recently. In the past week, Veeva Systems Inc. (NYSE:VEEV) has gained over 11.5% following the acquisition of Copli and the launch of the AI-driven […]

VEEV expands its AI push with Copli acquisition and Falcon MLR launch, aiming to speed life sciences content reviews and boost Commercial Cloud.

Veeva Systems Inc. (NYSE:VEEV) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 23, Veeva Systems Inc. (NYSE:VEEV) announced that it acquired Copli and launched Veeva Falcon MLR. It made the agentic medical, legal, and regulatory content-review platform available immediately. The firm said Veeva Falcon MLR automates […]

If you are wondering whether Veeva Systems stock offers good value at its current price, it can help to step back from the headlines and look at how different valuation methods compare. The stock last closed at US$171.36, with recent moves including an 11.8% gain over the past week and an 8.1% gain over the past month. Year to date the price is down 21.9% and the 1 year return is down 39.5%. These mixed returns sit against a backdrop where investors are paying closer attention to Veeva...

Earlier this week, Veeva Systems expanded its Quality Cloud with the launch of Veeva EHS and advanced its AI transition through acquisitions like Copli, while reporting double-digit revenue growth and raising its full-year outlook. Together, these moves deepen Veeva’s role in life sciences workflows by integrating AI-driven automation across compliance, safety, and content review, potentially reshaping how customers manage risk and regulatory complexity. We’ll now examine how the launch of...

VEEV's Veeva EHS expands Quality Cloud with automated risk, compliance and safety workflows, aiming to replace legacy systems with a unified platform.

Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Brown Capital Management, an investment management company, released its first quarter 2026 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded here. In the first quarter of 2026, the Small Company Fund (Investor shares) fell 19.78%, significantly lagging the Russell 2000 Growth index’s 2.81% decline. Worsened […]

Veeva Systems Inc. (NYSE:VEEV) is one of the most promising stocks with highest upside potential. On June 3, Veeva Systems reported strong financial results for its FQ1 2027, with total revenues reaching $882.9 million, a 16% increase year-over-year. Subscription revenues also saw steady growth, rising 15% to $730.2 million. The company exceeded its guidance across […]

Though Veeva Systems has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

It may be a great time to "buy low."

A number of stocks fell in the afternoon session after the Federal Reserve held its benchmark rate at 3.5%–3.75%, unchanged since the central bank cut by three-quarters of a point in late 2025, and then delivered a dot plot that told investors the easing cycle underpinning the sector's re-rating might be over.

Veeva Systems Inc. (NYSE:VEEV) is one of the 10 Best Debt-Free American Stocks to Invest In. On June 4, 2026, Mizuho analyst Steven Valiquette lowered the firm’s price target on Veeva Systems Inc. (NYSE:VEEV) to $270 from $295 and maintained an Outperform rating on the shares. Valiquette updated Mizuho’s model following the Q1 report and […]

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how vertical software stocks fared in Q1, starting with Veeva Systems (NYSE:VEEV).

Burry said separately that while AI-fueled stocks are headed for correction, value stocks are emerging.

Veeva Systems (NYSE:VEEV) has been selected by UCB to deploy its Safety Suite across the biopharmaceutical company's global operations. The deal focuses on unifying UCB's worldwide pharmacovigilance activities on Veeva's integrated platform. This win expands Veeva's customer base among large global biopharmaceutical companies and highlights uptake of its safety offerings. Veeva Systems, known for its cloud software for life sciences, has been rolling out broader offerings that connect...

VEEV's UCB pharmacovigilance deal expands Safety Suite adoption, supporting automation, compliance and long-term growth opportunities.

Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

VEEV's strong Q1, growing Vault CRM migrations and AI expansion support growth, though life sciences CRM market saturation poses risks.

Despite GE HealthCare's underperformance relative to the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Veeva Systems’ first quarter saw meaningful progress across its core business lines, with management attributing the results to broad-based customer demand and product execution in both R&D and commercial segments. CEO Peter Gassner highlighted the launch of Veeva’s Falcon platform as a key milestone, describing it as a shift toward “agentic labor”—using AI agents to automate specialized industry tasks. Strong service execution and continued innovation in measurement tools like Crossix also cont

If you are looking at Veeva Systems and wondering whether the recent price is fair, expensive, or offers value, the next sections break down what the current valuation actually reflects. The stock last closed at US$167.68, after a mixed run with the price down 8.3% over the past week, roughly flat over 30 days with a 0.8% gain, and declining 23.6% year to date and 41.0% over the past year. Recent headlines around Veeva Systems have focused on its position as a healthcare software provider...

VEEV's Falcon and Vault AI deepen workflow automation across life sciences, while management expects AI revenues to remain immaterial in fiscal 2027.